The NINDS Parkinson's Disease Biomarkers Program (PDBP) was established to advance discovery of biomarkers that will improve the efficiency and outcome of Phase II clinical trials for Parkinson's Disease (PD) and advance therapeutic development for PD. The PDBP was setup to cover the spectrum of Parkinson's disease from first diagnosis to more advance stages of the disease and includes the longitudinal collection of clinical data and biospecimens. Since the program began in November of 2012, six clinical sites have enrolled more than 800 participants in the study, and over 12,000 clinical forms are available through the PDBP data management resource (DMR). Each participating clinical site follows a standardized schedule for patient visits and clinical data collection. Also, through a standardized set of procedures, biospecimens are collected and stored at the NINDS Repository. There are currently over 200 cerebropinal fluid samples (CSF) and more than 500 RNA, plasma and serum samples available for analysis. These biospecimens and associated quality control data on the biospecimens are available through the NINDS Repository catalog in the PDBP DMR. Requests for biospecimens are handled through the PDBP Biospecimen Resource Access Committee (BRAC). The relationship of clinical data with the biospecimen is initially blinded to investigators using these samples. Upon completion of biomarker measurements and disposition of the associated data with the PDBP DMR, biospecimens used in the study will be unblinded. Access to this data by other investigators is embargoed for one year post sample identification.